ECM
SLNO

Eisler Capital Management’s Soleno Therapeutics SLNO Stock Holding History

Eisler Capital Management’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$20.3K Buy
+303
New +$22.5K ﹤0.01% 800

Other funds holding SLNO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Eisler Capital Management's SLNO Position: Q3 2025 in Review

Eisler Capital Management opened a new position in Soleno Therapeutics (SLNO) in Q3 2025: 303 shares worth $20.3K. The stake represents ﹤0.01% of the portfolio and ranks #800 among its holdings.

240 funds tracked by Wall St. Rank hold SLNO as of Q3 2025.

  • Eisler Capital Management held 303 shares of Soleno Therapeutics worth $20.3K as of Q3 2025.
  • Soleno Therapeutics was a new Eisler Capital Management position in Q3 2025.
  • Soleno Therapeutics made up ﹤0.01% of Eisler Capital Management's portfolio in Q3 2025, its #800 holding.
  • 240 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q3 2025.

Based on Eisler Capital Management's 13F filing for Q3 2025, filed 13 Nov 2025.